Carly Szabo

From the bright lights of Broadway to the darkness of hepatitis C infection, effective new drugs help patient start life anew.

Urban caregivers on the front lines of fighting HCV.

Research may offer hope for hepatitis C patients with liver disease.

Panel suggests different regimens for different hepatitis C patient groups.

Hope on the horizon for patients with liver damage.

Risk for illness and death greater due to socioeconomic status of patients with hepatitis C.

Liver damage caused by hepatitis C may eventually be overcome through stem cell therapy.

Successful response to hepatitis C treatment shows a 30 percent increased reduction in liver stiffness.

Scientists discover threat from AAV2 virus and from correlation to the development of liver cancer.

NS3 enzyme interacts with RNA and helps the pathogen replication process.

Psychosis and hepatic fibrosis associated with earlier mortality.

Study finds potential link between HCV treatment and drug-induced hepatotoxicity.

Hepatitis C infection causes more deaths than HIV, hepatitis B, and tuberculosis combined.

Synthetic estrogen molecule may have a profound effect on the ability to survive major blood loss.

Near-fatal car accident leads man down long journey from infection to cure for hepatitis C.

Secondary prevention found to be unavailable and unaffordable in 94,919 communities across the world.

Patients treated with HIV therapy less likely to get infected with HBV.

Patients treated with HIV therapy less likely to get infected with HBV.

Study suggests increasing oxidative stress through with pro-oxidants may prevent metastasis.

Molecular mechanisms behind acute myeloid leukemia may offer a new target for drug development.

B cell depletion therapy decreases new disease activity in people with relapsing-remitting MS.

Specific vaccine-induced immune responses correlate with reduced HIV infection.

Multiple myeloma comorbidities may contribute to the development of pulmonary hypertension.

How treatment with Harvoni changed the life of a patient infected with HCV.

Intestinal microbiome found to influence MS disease emergence and progression.

Hormone treatment may prove to be effective alternative option for patients with invasive lobular carcinoma.

Nanoforumulated protease inhibitor protects HIV drug from being degraded by the liver and removed by the kidney.

Side effects, familial support and liver condition among factors that influence hepatitis C treatment decisions.

New payment models hold care providers accountable for the full spectrum of patient care.

Genetic information may help develop treatment guidelines for Crohn's disease and ulcerative colitis.